Kontakt
GBG Forschungs GmbH
Martin-Behaim-Straße 12
63263 Neu-Isenburg
Tel.: +49610274800
Fax: +4961027480440
E-Mail: Infgbgd
Kontaktformular
News
07.05.2019 AURORA: inital results presented
The initial results of AURORA were announced at the ESMO Breast Cancer Congress in Berlin.
Mehr ...02.05.2019 GBG Research at ESMO Breast Cancer 2019
Data of several GBG research projects will be presented at the ESMO Breast Cancer 2019, which takes place from 2 to 4 May in Berlin, Germany.
Mehr ...10.04.2019 Results from E-VITA trial conducted with HER2-positive metastatic breast cancer patients
We are pleased to inform you that the results of the E-VITA study that evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER2-positive metastatic breast cancer has been published in the Anticancer Drugs.
Mehr ...01.03.2019 Evaluation of sCAIX as predictive marker for efficacy of neoadjuvant bevacizumab
A translational research study performed with samples obtained from a cohort of patients with HER2-negative breast cancer enrolled in the neoadjuvant GeparQuinto (GBG 44) trial has been published in the International Journey of Cancer.
Mehr ...04.02.2019 ESMO Breast Cancer 2019
ESMO Breast Cancer is an annual congress taking place on 2-4 May 2019 in Berlin, Germany.
Mehr ...
GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440